CL2020000919A1 - Anticuerpos específicos cd47/pd-l1. - Google Patents
Anticuerpos específicos cd47/pd-l1.Info
- Publication number
- CL2020000919A1 CL2020000919A1 CL2020000919A CL2020000919A CL2020000919A1 CL 2020000919 A1 CL2020000919 A1 CL 2020000919A1 CL 2020000919 A CL2020000919 A CL 2020000919A CL 2020000919 A CL2020000919 A CL 2020000919A CL 2020000919 A1 CL2020000919 A1 CL 2020000919A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody
- same
- specific antibodies
- antibodies
- present
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 1
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 1
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 abstract 1
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A LA BIOTECNOLOGÍA, EN PARTICULAR A ANTICUERPOS O FRAGMENTOS DE UNIÓN A ANTÍGENO DE LOS MISMOS, Y AL USO DE LOS MISMOS. MÁS PARTICULARMENTE, LA PRESENTE INVENCIÓN SE REFIERE A ANTICUERPOS QUE SE UNEN ESPECÍFICAMENTE A CD47 Y PD-L1. LA INVENCIÓN TAMBIÉN SE REFIERE A UN ÁCIDO NUCLEICO QUE CODIFICA DICHO ANTICUERPO O FRAGMENTO DE UNIÓN A ANTÍGENO DEL MISMO, UN VECTOR DE EXPRESIÓN, UN MÉTODO PARA PREPARAR DICHO ANTICUERPO Y EL USO DE DICHOS ANTICUERPOS Y COMPOSICIONES EN TERAPIAS CONTRA EL CÁNCER.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201791961A EA039662B1 (ru) | 2017-10-03 | 2017-10-03 | Антитела, специфичные к cd47 и pd-l1 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020000919A1 true CL2020000919A1 (es) | 2020-10-16 |
Family
ID=65994976
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020000919A CL2020000919A1 (es) | 2017-10-03 | 2020-04-03 | Anticuerpos específicos cd47/pd-l1. |
Country Status (21)
Country | Link |
---|---|
US (1) | US11840567B2 (es) |
EP (1) | EP3693390A4 (es) |
JP (2) | JP2020535839A (es) |
KR (1) | KR20200058542A (es) |
CN (1) | CN111801352A (es) |
AR (1) | AR113342A1 (es) |
AU (1) | AU2018345458A1 (es) |
BR (1) | BR112020006706A2 (es) |
CA (1) | CA3078413A1 (es) |
CL (1) | CL2020000919A1 (es) |
CO (1) | CO2020004199A2 (es) |
EA (1) | EA039662B1 (es) |
EC (1) | ECSP20024555A (es) |
JO (1) | JOP20200078A1 (es) |
MA (1) | MA49599B1 (es) |
MX (1) | MX2020004027A (es) |
PE (1) | PE20210460A1 (es) |
PH (1) | PH12020550214A1 (es) |
TW (1) | TWI768129B (es) |
WO (1) | WO2019068302A1 (es) |
ZA (1) | ZA202002047B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3035681A1 (en) | 2016-09-29 | 2018-04-05 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
MX2019005858A (es) | 2016-11-18 | 2019-08-12 | Beijing Hanmi Pharmaceutical Co Ltd | Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo. |
JP7231641B2 (ja) * | 2017-12-04 | 2023-03-01 | 北京韓美薬品有限公司 | 天然抗体様構造を有し、ヘテロ二量体形態の抗pd-l1/抗cd47二重特異性抗体、ならびにその製造方法 |
CN109970860A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
CA3084518A1 (en) | 2018-01-15 | 2019-07-18 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against pd-1 |
WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
EP3564263A1 (en) * | 2018-05-03 | 2019-11-06 | Universitätsklinikum Hamburg-Eppendorf | Fusion proteins comprising a cell surface marker specific vhh |
EP3969484A4 (en) * | 2019-05-17 | 2023-07-05 | Nanjing GenScript Biotech Co., Ltd. | ANTI-CD47/ANTI-PD-L1 MULTIPLE ANTIGEN BINDING PROTEINS AND METHODS OF USE |
JP2022540781A (ja) * | 2019-06-25 | 2022-09-20 | イノベント バイオロジクス(スーチョウ)カンパニー,リミティド | 抗cd47/pd‐l1二重特異性抗体を含む製剤、その調製方法及び使用 |
US20220332824A1 (en) * | 2019-07-08 | 2022-10-20 | Nanjing GenScript Biotech Co., Ltd. | Anti-cd47/anti-pd-1 bispecific antibody, preparation method and use thereof |
CN115052884A (zh) * | 2019-09-27 | 2022-09-13 | 北京烁星生物医药科技有限公司 | 单特异性和多特异性抗体 |
CN112745392B (zh) * | 2019-10-30 | 2022-07-01 | 上海洛启生物医药技术有限公司 | 抗pd-l1/cd47双特异性抗体及其用途 |
IL293926A (en) | 2019-12-17 | 2022-08-01 | Pfizer | Antibodies unique to d47, pd-l1 and their uses |
EP4105234A4 (en) * | 2020-02-12 | 2024-04-03 | Shanghai Escugen Biotechnology Co., Ltd. | SINGLE-DOMAIN ANTIBODY TARGETING HUMAN CD47 AND USE THEREOF |
WO2022057939A1 (en) * | 2020-09-21 | 2022-03-24 | I-Mab Biopharma Co., Ltd. | Pharmaceutical composition comprising cd47 antibody and pd-1/pd-l1 inhibitor |
EP4242232A1 (en) * | 2020-11-06 | 2023-09-13 | Bio-Thera Solutions, Ltd. | Bispecific antibody and use thereof |
CN114478770A (zh) * | 2020-11-12 | 2022-05-13 | 迈威(上海)生物科技股份有限公司 | 抗体及其制备方法 |
US20240132627A1 (en) * | 2021-02-19 | 2024-04-25 | Shaperon Inc. | Bispecific single domain antibody to pd-l1 and cd47 and use thereof |
JP2024513643A (ja) * | 2021-02-19 | 2024-03-27 | シャペロン インク. | Pd-l1に対する単一ドメイン抗体及びその用途 |
EP4296282A1 (en) * | 2021-02-19 | 2023-12-27 | SHAPERON Inc. | Single domain antibody against cd47 and use thereof |
BR112023023270A2 (pt) * | 2021-05-07 | 2024-01-30 | Immuneoncia Therapeutics Inc | Anticorpo biespecífico que se liga especificamente a cd47 e pd-l1 |
BR112023026982A2 (pt) * | 2021-06-21 | 2024-03-12 | Biocad Joint Stock Co | Anticorpo biespecífico isolado, ácido nucleico, vetor de expressão, método para produzir uma célula hospedeira, célula hospedeira, método para produzir o anticorpo biespecífico, composição farmacêutica e uso do anticorpo |
CN115702931A (zh) * | 2021-08-06 | 2023-02-17 | 百奥泰生物制药股份有限公司 | 抗pd-l1/cd47双特异抗体在治疗疾病中的应用 |
WO2023051680A1 (zh) * | 2021-09-30 | 2023-04-06 | 正大天晴药业集团股份有限公司 | 针对免疫检查点的双特异性抗体 |
WO2023154730A2 (en) * | 2022-02-09 | 2023-08-17 | Exelixis, Inc. | Multispecific binding agents and uses thereof |
KR20230163305A (ko) * | 2022-05-19 | 2023-11-30 | (주)샤페론 | Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도 |
WO2024022384A1 (en) * | 2022-07-28 | 2024-02-01 | Shenzhen Enduring Biotech , Ltd. | Peg based anti-cd47/anit-pd-l1 bispecific antibody-drug conjugate |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1991000360A1 (en) | 1989-06-29 | 1991-01-10 | Medarex, Inc. | Bispecific reagents for aids therapy |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
WO1992000373A1 (en) | 1990-06-29 | 1992-01-09 | Biosource Genetics Corporation | Melanin production by transformed microorganisms |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP0625200B1 (en) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Biosynthetic binding protein for cancer marker |
JPH08500017A (ja) | 1992-08-17 | 1996-01-09 | ジェネンテク,インコーポレイテッド | 二特異的免疫アドヘジン |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
CA2226962A1 (en) | 1998-02-16 | 1999-08-16 | Marie Sarfati | Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection |
CA2925551A1 (en) | 1999-08-23 | 2001-03-01 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
JP2004535542A (ja) | 2000-08-18 | 2004-11-25 | リンデ アクチエンゲゼルシヤフト | 空気分離設備の製造法 |
AU2002258941A1 (en) | 2001-04-20 | 2002-11-05 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
HUE026039T2 (en) | 2005-07-01 | 2016-05-30 | Squibb & Sons Llc | Human monoclonal antibodies programmed for death ligand 1 (PD-L1) |
EP2262837A4 (en) * | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
KR101924874B1 (ko) | 2008-09-26 | 2018-12-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-pd-1, pd-l1, 및 pd-l2 항체 및 그의 용도 |
EP2376535B9 (en) | 2008-12-09 | 2017-09-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
HUE049647T2 (hu) | 2009-11-24 | 2020-09-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
LT3789038T (lt) | 2010-05-14 | 2022-12-12 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizuoti ir chimeriniai monokloniniai antikūnai prieš cd47 |
BR112014019331A2 (pt) | 2012-02-06 | 2022-07-12 | Inhibrx Inc | anticorpos para cd47 e métodos de uso desses |
JP6392770B2 (ja) * | 2012-12-03 | 2018-09-19 | ノビミューン エスアー | 抗cd47抗体およびその使用方法 |
BR112015013431A2 (pt) | 2012-12-12 | 2017-11-14 | Vasculox Inc | anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos |
GB201300706D0 (en) | 2013-01-15 | 2013-02-27 | Cancer Rec Tech Ltd | Antibody |
EP2953643B1 (en) | 2013-02-06 | 2023-02-22 | Inhibrx, Inc. | Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof |
WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
WO2016061142A1 (en) * | 2014-10-14 | 2016-04-21 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
WO2017053423A1 (en) | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
RU2665790C1 (ru) * | 2017-04-17 | 2018-09-04 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело к pd-l1 |
-
2017
- 2017-10-03 EA EA201791961A patent/EA039662B1/ru unknown
-
2018
- 2018-09-28 TW TW107134503A patent/TWI768129B/zh active
- 2018-10-03 CN CN201880078338.5A patent/CN111801352A/zh active Pending
- 2018-10-03 US US16/753,587 patent/US11840567B2/en active Active
- 2018-10-03 AU AU2018345458A patent/AU2018345458A1/en active Pending
- 2018-10-03 KR KR1020207012767A patent/KR20200058542A/ko active Search and Examination
- 2018-10-03 CA CA3078413A patent/CA3078413A1/en active Pending
- 2018-10-03 MX MX2020004027A patent/MX2020004027A/es unknown
- 2018-10-03 MA MA49599A patent/MA49599B1/fr unknown
- 2018-10-03 BR BR112020006706-7A patent/BR112020006706A2/pt unknown
- 2018-10-03 WO PCT/EA2018/050001 patent/WO2019068302A1/ru unknown
- 2018-10-03 EP EP18864490.0A patent/EP3693390A4/en active Pending
- 2018-10-03 JP JP2020519341A patent/JP2020535839A/ja active Pending
- 2018-10-03 JO JOP/2020/0078A patent/JOP20200078A1/ar unknown
- 2018-10-03 PE PE2020000513A patent/PE20210460A1/es unknown
- 2018-10-04 AR ARP180102862A patent/AR113342A1/es unknown
-
2020
- 2020-04-03 PH PH12020550214A patent/PH12020550214A1/en unknown
- 2020-04-03 CL CL2020000919A patent/CL2020000919A1/es unknown
- 2020-04-08 CO CONC2020/0004199A patent/CO2020004199A2/es unknown
- 2020-05-04 ZA ZA2020/02047A patent/ZA202002047B/en unknown
- 2020-05-06 EC ECSENADI202024555A patent/ECSP20024555A/es unknown
-
2023
- 2023-07-07 JP JP2023112302A patent/JP2023130455A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EA201791961A1 (ru) | 2019-04-30 |
WO2019068302A1 (ru) | 2019-04-11 |
KR20200058542A (ko) | 2020-05-27 |
TWI768129B (zh) | 2022-06-21 |
AU2018345458A1 (en) | 2020-05-14 |
EA039662B1 (ru) | 2022-02-24 |
US20200270345A1 (en) | 2020-08-27 |
MA49599A1 (fr) | 2021-01-29 |
RU2020115122A (ru) | 2021-10-29 |
MA49599B1 (fr) | 2023-05-31 |
PH12020550214A1 (en) | 2021-02-15 |
ECSP20024555A (es) | 2020-06-30 |
PE20210460A1 (es) | 2021-03-08 |
EP3693390A1 (en) | 2020-08-12 |
CA3078413A1 (en) | 2019-04-11 |
EP3693390A4 (en) | 2021-11-03 |
CN111801352A (zh) | 2020-10-20 |
AR113342A1 (es) | 2020-04-22 |
JP2023130455A (ja) | 2023-09-20 |
MX2020004027A (es) | 2020-08-13 |
TW201922781A (zh) | 2019-06-16 |
AU2018345458A2 (en) | 2020-05-21 |
JOP20200078A1 (ar) | 2020-04-30 |
BR112020006706A2 (pt) | 2020-10-06 |
JP2020535839A (ja) | 2020-12-10 |
CO2020004199A2 (es) | 2020-04-24 |
US11840567B2 (en) | 2023-12-12 |
ZA202002047B (en) | 2022-08-31 |
RU2020115122A3 (es) | 2021-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020000919A1 (es) | Anticuerpos específicos cd47/pd-l1. | |
CO2017008462A2 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
CO2018011364A2 (es) | Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos | |
CO2018000887A2 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
ECSP18023386A (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CO2018002446A2 (es) | Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas | |
CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
CL2019003520A1 (es) | Anticuerpos que se unen específicamente a pd-1 y procedimientos de uso. | |
BR112018012352A2 (pt) | anticorpos anti-lag3 e fragmentos de ligação ao antígeno | |
PE20171103A1 (es) | Anticuerpos heterodimericos que se unen a cd3 y cd38 | |
AR101400A1 (es) | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido | |
CO2019001367A2 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
BR112018012344A2 (pt) | anticorpos que se ligam especificamente a hla-dr e seus usos | |
CL2017002596A1 (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
CL2019002894A1 (es) | Anticuerpo monoclonal para pd-l1. | |
CL2020000467A1 (es) | Anticuerpos multiespecíficos que se unen específicamente a los epítopos del virus del zika y usos de los mismos. | |
AR118763A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
AR099604A1 (es) | Anticuerpos de metaloproteinasa de matriz 9 y sus métodos de uso | |
CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. | |
UY37915A (es) | Anticuerpos específicos para cd47 y pd-l1 |